Results 201 to 210 of about 213,106 (383)

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi   +3 more
wiley   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Anaemia and renal dysfunction are independently associated with BNP and NT‐proBNP levels in patients with heart failure [PDF]

open access: bronze, 2007
Jochem Hogenhuis   +6 more
openalex   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer   +25 more
wiley   +1 more source

Left atrial enlargement and NT‐proBNP as predictors of sudden cardiac death in patients with heart failure [PDF]

open access: bronze, 2007
Antoni Bayés‐Genís   +18 more
openalex   +1 more source

Association between anaemia and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP): Findings from the Heart and Soul Study [PDF]

open access: bronze, 2007
Arati Desai   +5 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers

open access: green, 2004
Paul Collinson   +5 more
openalex   +1 more source

The relation between electrocardiographic ST-T changes and NT-proBNP in patients with acute ischemic stroke [PDF]

open access: bronze, 2007
Jesper K. Jensen   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy